TY - JOUR
T1 - Long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms
T2 - A population-based study
AU - Poleé, Iris N.
AU - Hermans, Bregtje C.M.
AU - van der Zwan, Jan Maarten
AU - Bouwense, Stefan A.W.
AU - Dercksen, Marcus W.
AU - Eskens, Ferry A.L.M.
AU - Havekes, Bastiaan
AU - Hofland, Johannes
AU - Kerkhofs, Thomas M.A.
AU - Klümpen, Heinz Josef
AU - Latten-Jansen, Loes M.
AU - Speel, Ernst Jan M.
AU - Verburg, Frederik A.
AU - Walenkamp, Annemiek M.E.
AU - Geurts, Sandra M.E.
AU - de Vos-Geelen, Judith
N1 - Funding Information:
EJMS has served as an advisory board member for Amgen, Lilly, Novartis and AstraZeneca, has received institutional research funding from AstraZeneca, Pfizer, Novartis and Bayer, and has received non-financial support from Biocartis and Abbvie. All outside the submitted work.
Funding Information:
FAV has received consultancy fees from Sanofi and EISAI, speaker honoraria from Sanofi and research support from EISAI. All outside the submitted work.
Funding Information:
AMEW reports institutional research grants and study funding from IPSEN, Novartis, Abbvie, BMS, Genzyme, Karyopharm Therapeutics, Roche and Polyphor. All outside the submitted work.
Funding Information:
SMEG has received institutional research funding from Roche, Pfizer, Novartis, and Eli Lilly. All outside the submitted work.
Funding Information:
JdV has served as a consultant for Amgen, AstraZeneca, MSD, Pierre Fabre and Servier, and has received institutional research funding from Servier. All outside the submitted work.
Publisher Copyright:
© 2022 The Author(s)
PY - 2022/9
Y1 - 2022/9
N2 - Background: Gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) comprise a group of rare malignant tumours with heterogeneous behaviour. This study aimed to assess long-term survival and prognostic factors associated with survival, in order to optimise counselling.Patients and methods: This population-based study included all GEP-NENs diagnosed between 1989 and 2016 in the Netherlands, selected from the Netherlands Cancer Registry. Overall survival (OS) and relative survival (RS) were calculated. A Cox Proportional Hazard analysis was used to identify prognostic factors (gender, age, tumour stage, location and treatment) for OS. Analyses were stratified by metastatic disease status and tumour grade.Results: In total, 9697 patients were included. In grade 1, 2 and 3 non-metastatic GEP-NENs (N = 6544), 5-year OS and RS were 81% and 88%, 78% and 83%, and 26% and 30%, respectively. In grade 1 non-metastatic GEP-NENs 10-year OS and RS were 68% and 83%. In grade 1, 2 and 3 metastatic GEP-NENs (N = 3153), 5-year OS and RS rates were 47% and 52%, 38% and 41%, and 5% and 5%, respectively. The highest (relative) survival rates were found in appendicular and rectal NENs, demonstrating 10-year OS and RS of 87% and 93%, and 81% and 95%, respectively.Conclusions: These long-term follow-up data demonstrate significant differences in survival for different grades, tumour stage, and primary origin of GEP-NENs, with the most favourable overall and RS rates in patients with non-metastatic grade 1 appendicular and rectal NENs. This study demonstrates unique long-term OS and RS rates using combined stratification by tumour site, grade and stage.
AB - Background: Gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) comprise a group of rare malignant tumours with heterogeneous behaviour. This study aimed to assess long-term survival and prognostic factors associated with survival, in order to optimise counselling.Patients and methods: This population-based study included all GEP-NENs diagnosed between 1989 and 2016 in the Netherlands, selected from the Netherlands Cancer Registry. Overall survival (OS) and relative survival (RS) were calculated. A Cox Proportional Hazard analysis was used to identify prognostic factors (gender, age, tumour stage, location and treatment) for OS. Analyses were stratified by metastatic disease status and tumour grade.Results: In total, 9697 patients were included. In grade 1, 2 and 3 non-metastatic GEP-NENs (N = 6544), 5-year OS and RS were 81% and 88%, 78% and 83%, and 26% and 30%, respectively. In grade 1 non-metastatic GEP-NENs 10-year OS and RS were 68% and 83%. In grade 1, 2 and 3 metastatic GEP-NENs (N = 3153), 5-year OS and RS rates were 47% and 52%, 38% and 41%, and 5% and 5%, respectively. The highest (relative) survival rates were found in appendicular and rectal NENs, demonstrating 10-year OS and RS of 87% and 93%, and 81% and 95%, respectively.Conclusions: These long-term follow-up data demonstrate significant differences in survival for different grades, tumour stage, and primary origin of GEP-NENs, with the most favourable overall and RS rates in patients with non-metastatic grade 1 appendicular and rectal NENs. This study demonstrates unique long-term OS and RS rates using combined stratification by tumour site, grade and stage.
KW - Carcinoid
KW - Gastrointestinal
KW - Neuroendocrine tumours
KW - Pancreas
KW - Population-based
KW - Prognosis
KW - Survival
U2 - 10.1016/j.ejca.2022.06.003
DO - 10.1016/j.ejca.2022.06.003
M3 - Article
AN - SCOPUS:85133479876
SN - 0959-8049
VL - 172
SP - 252
EP - 263
JO - European Journal of Cancer
JF - European Journal of Cancer
ER -